This site is intended for healthcare professionals
News

CHMP recommends Lynparza to treat metastatic castration-resistant prostate cancer with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations.- AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:22th Sep 2020
Published:22th Sep 2020
Condition: Prostate Cancer
Type: drug
Register free for full access to medthority.com